

August 1, 2008

## **Astellas Announces Acquisition of Treasury Stock**

(Acquisition of treasury stock pursuant to the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Japan, August 1, 2008 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted acquisition of treasury stock pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

### Particulars

1. Reasons for the acquisition of treasury stock  
To improve capital efficiency and enhance return to shareholders.
  
  2. Contents of acquisition
    - (1) Class of shares to be acquired: Common stock of the Company
    - (2) Total number of shares to be acquired: 10 million shares (maximum)  
(The percentage compared to the total number of shares outstanding: 2.04%)
    - (3) Aggregate amount of acquisition cost: 50 billion yen (maximum)
    - (4) Period of acquisition: From August 4, 2008 to August 21, 2008
- (Reference)  
The status of treasury stock as of June 30, 2008:  
Total number of shares outstanding: 488,998,321 shares  
Number of treasury stock: 14,966,314 shares

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 <a href="http://www.astellas.com">http://www.astellas.com</a>